Adaptimmune Therapeutics plc

  • Home
  • Our Company
    • Overview arrow_forward
    • Partners arrow_forward
    • Board of Directors arrow_forward
    • Leadership Team arrow_forward
    • Scientific Advisory Board arrow_forward
    • Perspectives arrow_forward
    • COVID-19 arrow_forward
  • Pipeline
    • Overview arrow_forward
    • ADP-A2M4 arrow_forward
    • ADP-A2M4CD8 arrow_forward
    • ADP-A2AFP arrow_forward
    • ADP-A2M10 arrow_forward
  • Technology
    • Overview arrow_forward
    • Manufacturing arrow_forward
    • Publications arrow_forward
  • Patients & Families
    • Overview arrow_forward
    • Taking Part in Our Clincial Trials arrow_forward
    • Cancer Info arrow_forward
    • Cancer Immunotherapy Month arrow_forward
    • Videos arrow_forward
    • Engagement with Patient Organizations arrow_forward
  • Clinical Trials
  • Investors & Media
    • Overview arrow_forward
    • News & Events arrow_forward
    • Annual Shareholder Meeting arrow_forward
    • Company Info arrow_forward
    • Financial Info arrow_forward
    • Stock Data arrow_forward
    • SEC Filings arrow_forward
    • Governance arrow_forward
    • Media arrow_forward
  • Contact
  • Careers
    • Overview arrow_forward
    • U.S. Careers arrow_forward
    • UK Careers arrow_forward

Press Releases

Investors & Media

Investors & Media

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Annual Shareholder Meeting
  • Company Info
    • Overview
    • Leadership Team
    • Board of Directors
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Media
  • News & Media

  • Press Releases
  • Presentations
  • Events
Oct 20, 2018 10:45am EDT

Updated Data from Ongoing MAGE-A10 and MAGE-A4 Studies Presented at the 2018 ESMO Congress

Oct 08, 2018 6:10pm EDT

Data Updates from Ongoing MAGE-A10 Studies and MAGE-A4 Study to be presented at the European Society for Medical Oncology (ESMO) 2018 Congress

Sep 07, 2018 1:14pm EDT

Adaptimmune Therapeutics plc Announces Closing of Registered Direct Offering of American Depositary Shares

Sep 05, 2018 7:30am EDT

Adaptimmune Therapeutics plc Announces Registered Direct Offering of American Depositary Shares

Aug 15, 2018 7:30am EDT

Third Dosing Cohort to be initiated in MAGE-A4 SPEAR T-cell Basket Study After Favorable Review of Safety from One Billion Cell Dose Cohort

Aug 02, 2018 7:30am EDT

Adaptimmune Reports Second Quarter 2018 Financial Results and Business Update

Jul 26, 2018 1:18pm EDT

Adaptimmune to Report Second Quarter 2018 Financial Results and Business Update on Thursday August 2, 2018

Jul 24, 2018 7:30am EDT

GSK and Adaptimmune Complete Transition of NY-ESO SPEAR T-cell Therapy Program to GSK

Jul 18, 2018 7:29am EDT

Adaptimmune Announces Favorable Review of Safety from One Billion Cell Dose Cohort in MAGE-A10 SPEAR T-cell Study and Initiation of Third Dosing Cohorts

Jun 11, 2018 7:30am EDT

Study published in Cancer Discovery Indicates that NY-ESO SPEAR T-cells are Long-lived, Self‑renewing, and Capable of Persistent Anti-Tumor Effects

RSS
  • Prev
  • 1...
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • ...19
  • Next
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed
Adaptimmune Therapeutics plc
Privacy Policy Disclaimer Search Sitemap Terms of Use Supply Terms
Linedin Twitter Youtube
© 2021 Adaptimmune Therapeutics plc. All Rights Reserved.